NCT03199586View on ClinicalTrials.gov

Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

December 21, 2017

Primary Completion Date

May 7, 2020

Study Completion Date

May 7, 2020

Conditions
Breast CancerPancreas CancerProstate CancerLung CancerColon CancerEsophagus CancerLiver CancerOvary CancerAdvanced or Metastatic Treatment-refractory Solid Tumor Malignancies
Interventions
DRUG

NP-G2-044

capsule

Trial Locations (3)

10065

Memorial Sloan Kettering Hospital, New York

85258

HonorHealth Research Institute, Scottsdale

91010

City of Hope National Medical Center, Duarte

Sponsors
All Listed Sponsors
collaborator

Translational Drug Development

OTHER

lead

Novita Pharmaceuticals, Inc.

INDUSTRY

NCT03199586 - Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies | Biotech Hunter | Biotech Hunter